Your Article Summary
See Latest ArticlesActive Biotech Presents Data regarding the 57-57 SLE Project at EULAR
Active Biotech, 06/15/09
Active Biotech has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism (EULAR), an international event for specialists in the field of rheumatology, held in Copenhagen June 10-13. The patients in the Phase Ib trial were treated daily for 12 weeks with 57-57. The maximum tolerable dose was, as earlier communicated, defined at 4.5 mg/day.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09
Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09
Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Amylin Pharmaceuticals, 12/09/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease
AstraZeneca, 12/16/09
Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09
Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
Amylin Pharmaceuticals, 12/16/09